FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026348839> ?p ?o ?g. }

• W3026348839 endingPage "S204" @default.
• W3026348839 startingPage "S204" @default.
• W3026348839 abstract "Major depressive disorder (MDD) is associated with increased healthcare resources utilization, reduced quality-of-life, and substantial indirect costs. In the Kingdom of Saudi Arabia (KSA), there is a paucity of national-level data for MDD prevalence. A study reported a prevalence rate of 12% in the south-eastern region of the KSA. Vortioxetine and Sertraline have shown promising clinical results in MDD patients. However, these drugs are not yet included in the Ministry of Health (MoH) formulary of the KSA. This study assessed the budgetary impact (BI) of introducing vortioxetine and/or sertraline in the MoH formulary for the management of MDD patients. A BI model was developed to assess different scenarios — introducing Vortioxetine and/or Sertraline as first-line and/or second-line therapy, over a five-year time horizon. The key model inputs included the estimated number of MDD patients treated in MoH facilities, antidepressants market shares, escalation probability, adverse event rates and cost, treatment costs, and monitoring cost. Inputs were retrieved from literature and validated by key-experts through face-to-face interviews. The study demonstrated that the introduction of “only sertraline as first-line therapy” and “only vortioxetine as second-line” therapy increased the overall budget by 6.5% (SAR 15.9 million) and 8.9% (SAR 21.7 million), respectively compared to the status-quo. Introduction of “both sertraline as first-line and vortioxetine as second-line”, and “only vortioxetine as first-line” therapy resulted in a budget increase of 60.6% (SAR 147.3 million) and 72.7% (SAR 176.8 million), respectively compared to the status-quo. The introduction of sertraline and/or vortioxetine for the management of MDD patients in the KSA could overall increase the MoH budget. The increase in the budget would likely be lower with the introduction of “sertraline as first-line therapy” or “vortioxetine as second-line” therapy compared to introduction of “both vortioxetine first-line and sertraline second-line” and “vortioxetine as first-line” therapy." @default.
• W3026348839 created "2020-05-29" @default.
• W3026348839 creator A5018817732 @default.
• W3026348839 creator A5022165608 @default.
• W3026348839 creator A5031473386 @default.
• W3026348839 creator A5040942104 @default.
• W3026348839 creator A5056087556 @default.
• W3026348839 creator A5057574426 @default.
• W3026348839 creator A5073993737 @default.
• W3026348839 creator A5080652975 @default.
• W3026348839 creator A5088103195 @default.
• W3026348839 date "2020-05-01" @default.
• W3026348839 modified "2023-09-27" @default.
• W3026348839 title "PMH24 BUDGET IMPACT ANALYSIS OF VORTIOXETINE AND/OR SERTRALINE USE FOR MANAGEMENT OF MAJOR DEPRESSIVE DISORDER IN THE KINGDOM OF SAUDI ARABIA" @default.
• W3026348839 doi "https://doi.org/10.1016/j.jval.2020.04.644" @default.
• W3026348839 hasPublicationYear "2020" @default.
• W3026348839 type Work @default.
• W3026348839 sameAs 3026348839 @default.
• W3026348839 citedByCount "0" @default.
• W3026348839 crossrefType "journal-article" @default.
• W3026348839 hasAuthorship W3026348839A5018817732 @default.
• W3026348839 hasAuthorship W3026348839A5022165608 @default.
• W3026348839 hasAuthorship W3026348839A5031473386 @default.
• W3026348839 hasAuthorship W3026348839A5040942104 @default.
• W3026348839 hasAuthorship W3026348839A5056087556 @default.
• W3026348839 hasAuthorship W3026348839A5057574426 @default.
• W3026348839 hasAuthorship W3026348839A5073993737 @default.
• W3026348839 hasAuthorship W3026348839A5080652975 @default.
• W3026348839 hasAuthorship W3026348839A5088103195 @default.
• W3026348839 hasBestOaLocation W30263488391 @default.
• W3026348839 hasConcept C100406419 @default.
• W3026348839 hasConcept C118552586 @default.
• W3026348839 hasConcept C134362201 @default.
• W3026348839 hasConcept C169900460 @default.
• W3026348839 hasConcept C2777669559 @default.
• W3026348839 hasConcept C2778034309 @default.
• W3026348839 hasConcept C2779177272 @default.
• W3026348839 hasConcept C2780051608 @default.
• W3026348839 hasConcept C512399662 @default.
• W3026348839 hasConcept C558461103 @default.
• W3026348839 hasConcept C71924100 @default.
• W3026348839 hasConceptScore W3026348839C100406419 @default.
• W3026348839 hasConceptScore W3026348839C118552586 @default.
• W3026348839 hasConceptScore W3026348839C134362201 @default.
• W3026348839 hasConceptScore W3026348839C169900460 @default.
• W3026348839 hasConceptScore W3026348839C2777669559 @default.
• W3026348839 hasConceptScore W3026348839C2778034309 @default.
• W3026348839 hasConceptScore W3026348839C2779177272 @default.
• W3026348839 hasConceptScore W3026348839C2780051608 @default.
• W3026348839 hasConceptScore W3026348839C512399662 @default.
• W3026348839 hasConceptScore W3026348839C558461103 @default.
• W3026348839 hasConceptScore W3026348839C71924100 @default.
• W3026348839 hasLocation W30263488391 @default.
• W3026348839 hasOpenAccess W3026348839 @default.
• W3026348839 hasPrimaryLocation W30263488391 @default.
• W3026348839 hasRelatedWork W1917104769 @default.
• W3026348839 hasRelatedWork W2021856222 @default.
• W3026348839 hasRelatedWork W2073199500 @default.
• W3026348839 hasRelatedWork W2183172310 @default.
• W3026348839 hasRelatedWork W2507878460 @default.
• W3026348839 hasRelatedWork W2525957409 @default.
• W3026348839 hasRelatedWork W2732190617 @default.
• W3026348839 hasRelatedWork W2946691347 @default.
• W3026348839 hasRelatedWork W3026348839 @default.
• W3026348839 hasRelatedWork W3027254364 @default.
• W3026348839 hasVolume "23" @default.
• W3026348839 isParatext "false" @default.
• W3026348839 isRetracted "false" @default.
• W3026348839 magId "3026348839" @default.
• W3026348839 workType "article" @default.